---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-139500"
form_type: "8-K"
ticker: "PTPI"
cik: "0001815903"
company_name: "Petros Pharmaceuticals, Inc."
filed_at: "2021-11-16T23:59:59+00:00"
generated_at: "2026-06-28T07:52:33.510095+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Petros Pharma Q3 net sales fall 37% to $2.2M; net loss narrows to $1.7M

## Summary
- Net sales $2.2M, down from $3.5M YoY; Prescription Medicines net sales declined 47% due to higher allowances and returns.
- Net loss improved to $1.7M vs $3.3M YoY; adjusted EBITDA loss $1.9M.
- Record STENDRA prescriptions and tablet sales; total mg sold up 6% sequentially.
- Completed enrollment of pivotal label comprehension study for OTC switch of STENDRA; no FDA-approved OTC ED drug exists.
- Cash $8.1M at Sep 30; raised $5.3M net in October 2021.

## SEC filing metadata
- accession: 0001104659-21-139500
- form_type: 8-K
- ticker: PTPI
- cik: 0001815903
- company_name: Petros Pharmaceuticals, Inc.
- filed_at: 2021-11-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815903/000110465921139500/0001104659-21-139500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815903/000110465921139500/tm2133040d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-139500
- JSON: https://secwatch.observer/filing/0001104659-21-139500.json
- Plain text: https://secwatch.observer/filing/0001104659-21-139500.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.